Clinical Trials Using Montanide ISA 51 VG

Clinical trials are research studies that involve people. The clinical trials on this list are studying Montanide ISA 51 VG. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing Malignant Pleural Mesothelioma

    This phase I trial studies the side effects of a vaccine, galinpepimut-S, and nivolumab in treating patients with WT1 positive malignant pleural mesothelioma. Vaccines, such as galinpepimut-S, are made from Wilms Tumor Protein 1 (WT1) peptide and may help the body build an effective immune response to kill tumor cells that express WT1. Galinpepimut-S is mixed with a substance called montanide, which helps to boost the immune reaction to galinpepimut-S. The mixture of the galinpepimut-S and montanide make up the actual final vaccine that is then given to patients. Immunotherapy with monoclonal antibodies, such as nivolumab, may remove signals that block the immune system’s activity, indirectly strengthening the immune system to help fight the cancer. It has been shown that cancer vaccines can sometimes increase these signals that actually block the immune system’s anti-cancer activity. Using a cancer vaccine (galinpepimut-S) directed to mesothelioma cells with a drug that can unblock these negative signals (nivolumab) may help treat malignant pleural mesothelioma.
    Location: 7 locations

  • A Phase I Study of WT1 or NY-ESO-1 OLP4 Vaccine and Nivolumab For the Treatment of Recurrent Ovarian Cancer

    This phase I trial studies the side effects of nivolumab in combination with Wilms tumor 1 (WT1) vaccine or New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) protein overlapping long peptides (OLP4) vaccine in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) at least twice and is now in remission. Vaccines made from WT1 and NY-ESO-1 peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent. Montanide and Poly-ICLC have been shown to increase the effect of vaccines on the immune system. Giving WT1 or NY-ESO-1 vaccine together with nivolumab may work better in treating ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 7 locations